Provulis LLC


Current therapeutics in preclinical and clinical development.

Candidate biologics


PRV100 is a human recombinant protein analog of MIS. This proprietary biologic was demonstrated to have superior pharmacological characteristics compared to its parent protein. Preclinical proof of concept studies have shown that treatment with PRV100 during chemotherapy protects the ovaries from the damages of chemotherapy.  


PRV200 is our gene therapy platform for delivery of MIS proprietary analogs for the treatment of various ovarian and endocrine dysfunctions. PRV200 is also currently being evaluated in field trials as a non-surgical permanent contraceptive for use in pets.

Other candidates

Multiple MIS analogs are currently under evaluation for the treatment of rare endocrine disorders.